The U.S. FDA Approved BioMarin Pharmaceutical's ROCTAVIAN, the First and Only Gene Therapy for Adults with Severe Hemophilia A

BioMarin Pharmaceutical US FDA Approved ROCTAVIAN BioMarin Pharmaceutical ( BMRN ) announced that the U.S. FDA approved ROCTAVIAN (valoctocogene roxaparvovec-rvox) gene therapy for adults with severe...